Clinical Trials Logo

Clinical Trial Summary

Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose variable, in 1-3 fractions.


Clinical Trial Description

A single institution, safety lead-in phase II trial with SAbR to multiple metastatic sites concurrently administered with Nivolumab for patients with metastatic clear cell renal cell cancer who have failed at least one anti-angiogenic therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02781506
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Terminated
Phase Phase 2
Start date June 20, 2016
Completion date May 24, 2021

See also
  Status Clinical Trial Phase
Completed NCT01510119 - Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT01896271 - High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Phase 2
Recruiting NCT06059014 - Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer Phase 1/Phase 2
Active, not recruiting NCT05122546 - CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Phase 1
Active, not recruiting NCT04904302 - Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Phase 2
Recruiting NCT04510597 - Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial Phase 3
Recruiting NCT06399419 - CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Phase 1
Not yet recruiting NCT06361810 - PSMA Therapy and Immunotherapy in Kidney Cancer Phase 1/Phase 2
Recruiting NCT06428708 - [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma Early Phase 1
Recruiting NCT04370509 - Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery Phase 2
Recruiting NCT05012371 - Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer Phase 2
Terminated NCT03334409 - Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery Phase 2
Completed NCT02848768 - Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma N/A
Recruiting NCT05361720 - Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Phase 2
Terminated NCT03260504 - Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Phase 1
Terminated NCT01391130 - A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT02002312 - Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Phase 2
Recruiting NCT04388852 - DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Phase 1
Recruiting NCT05879471 - 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT06349642 - Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform